Brief: Aurinia Pharmaceuticals Q3 Operating Income USD 11.748 Million
07/11/2024 11:00
Nov 07 (Reuters) - Aurinia Pharmaceuticals Q3 net income USD 14.35 million. * Q3 pretax profit USD 14.807 million * Q3 product revenue USD 55.503 million
Recent news on Aurinia Pharmaceuticals
See all newsBrief: Aurinia Settles Patent Litigation With Teva
Canada's Aurinia Q2 revenue rises on LUPKYNIS sales
Brief: Aurinia Pharmaceuticals Q2 Pretax Profit USD 48.786 Million
Aurinia Pharmaceuticals Inc expected to post earnings of 24 cents a share - Earnings Preview
Brief: Lupkynis Associated With A Statistically Significant 53% Reduction In Risk Of Renal-Related Event Or Death